Ubs Group Ag Pardes Biosciences, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.4 - $1.95 $15,353 - $21,385	-10,967 Reduced 97.0%	339 $0
Q1 2023 May 12, 2023	SELL	$1.21 - $2.22 $5,954 - $10,924	-4,921 Reduced 30.33%	11,306 $14,000
Q4 2022 Feb 08, 2023	SELL	$0.85 - $1.69 $9,361 - $18,611	-11,013 Reduced 40.43%	16,227 $27,000
Q3 2022 Nov 10, 2022	BUY	$2.14 - $3.7 $7,652 - $13,231	3,576 Added 15.11%	27,240 $50,000
Q2 2022 Aug 10, 2022	BUY	$2.84 - $8.57 $66,779 - $201,514	23,514 Added 15676.0%	23,664 $72,000
Q4 2021 Feb 14, 2022	BUY	$9.8 - $17.02 $1,470 - $2,553	150 New	150 $2,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.